Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study.

IF 3.1 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-08-04 DOI:10.1080/14796694.2026.2713355

Shan Xu, Hao Yang, Nan Hu

{"title":"Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study.","authors":"Shan Xu, Hao Yang, Nan Hu","doi":"10.1080/14796694.2026.2713355","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to clarify the incidence of anthracycline-induced cardiotoxicity (ACT) and identify its clinical and candidate genetic risk factors in Chinese early-stage breast cancer patients, so as to provide evidence for clinical risk assessment and individualized cardiac protection.Methods: This study included 119 patients who received anthracycline-based chemotherapy. Cardiac function was assessed via echocardiography at baseline, post-chemotherapy, and at one-year follow-up. Five candidate SNPs (CBR3 rs1056892, GSTP1 rs1695, SLC28A3 rs7853758, ABCB1 rs1045642, ABCC2 rs8187710) were genotyped to analyze their association with ACT.Results: The incidence of ACT was 15.1% (18/119). No significant association was found between any of the five genotyped SNPs and the development of ACT (all p > 0.05). Multivariate logistic regression analysis identified older age, higher cumulative anthracycline dose, and the use of HER2-targeted antibodies (trastuzumab/pertuzumab) as independent clinical risk factors for ACT.Conclusion: In Chinese early-stage breast cancer patients, ACT is significantly associated with clinical risk factors rather than the selected candidate genetic polymorphisms. These findings support targeted cardiac monitoring and optimized treatment strategies for high-risk patients to reduce the occurrence of anthracycline-related cardiac injury.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2313-2321"},"PeriodicalIF":3.1000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2026.2713355","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to clarify the incidence of anthracycline-induced cardiotoxicity (ACT) and identify its clinical and candidate genetic risk factors in Chinese early-stage breast cancer patients, so as to provide evidence for clinical risk assessment and individualized cardiac protection.

Methods: This study included 119 patients who received anthracycline-based chemotherapy. Cardiac function was assessed via echocardiography at baseline, post-chemotherapy, and at one-year follow-up. Five candidate SNPs (CBR3 rs1056892, GSTP1 rs1695, SLC28A3 rs7853758, ABCB1 rs1045642, ABCC2 rs8187710) were genotyped to analyze their association with ACT.

Results: The incidence of ACT was 15.1% (18/119). No significant association was found between any of the five genotyped SNPs and the development of ACT (all p > 0.05). Multivariate logistic regression analysis identified older age, higher cumulative anthracycline dose, and the use of HER2-targeted antibodies (trastuzumab/pertuzumab) as independent clinical risk factors for ACT.

Conclusion: In Chinese early-stage breast cancer patients, ACT is significantly associated with clinical risk factors rather than the selected candidate genetic polymorphisms. These findings support targeted cardiac monitoring and optimized treatment strategies for high-risk patients to reduce the occurrence of anthracycline-related cardiac injury.

查看原文本刊更多论文

中国早期乳腺癌患者蒽环类药物引起心脏毒性的临床和遗传危险因素：一项候选基因研究

目的：本研究旨在明确蒽环类药物引起的心脏毒性（ACT）在中国早期乳腺癌患者中的发生率，并确定其临床和候选遗传危险因素，为临床风险评估和个体化心脏保护提供依据。方法：本研究纳入119例接受蒽环类化疗的患者。在基线、化疗后和一年随访时通过超声心动图评估心功能。对5个候选snp （CBR3 rs1056892、GSTP1 rs1695、SLC28A3 rs7853758、ABCB1 rs1045642、ABCC2 rs8187710）进行基因分型，分析其与ACT的相关性。结果：ACT的发生率为15.1%（18/119）。5个基因型snp均与ACT的发生无显著相关性（p < 0.05）。多因素logistic回归分析发现，年龄较大、蒽蒽类药物累积剂量较高、使用her2靶向抗体（曲妥珠单抗/帕妥珠单抗）是ACT的独立临床危险因素。结论：在中国早期乳腺癌患者中，ACT与临床危险因素显著相关，而与选定的候选遗传多态性无关。这些发现支持对高危患者进行针对性心脏监测和优化治疗策略，以减少蒽环类药物相关心脏损伤的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.